Brain+
0.128 DKK -0.39%Be the first to follow this company
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Denmark
BRAINP
Daily low / high price
0.128 / 0.128
DKK
Market cap
11.71M DKK
Turnover
7.04 DKK
Volume
55
Financial calendar
Annual report
07.05.2024
General meeting
15.05.2024
Interim report
29.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Kim Baden-Kristensen | 15.4 % | 15.4 % |
Ulrik Ditlev Eriksen | 9.3 % | 9.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Brain+ A/S: Brain+' CST-Assistant cited in leading Nordic Life Science magazine as an impactful health tech intervention for managing dementia
Brain+ A/S: Brain+ releases preliminary annual financial statements for 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools